Arteriovenous grafts in the thigh: an excellent hemodialysis vascular access when arm vasculature is exhausted.

The aim of our retrospective analysis with prospective collected data was to evaluate the patency of thigh expanded polytetrafluoroethylene (ePTFE) arteriovenous (AV) grafts, which were placed in chronic hemodialysis patients by the same interventional nephrologist skilled in hemodialysis access vascular surgery. From February 1991 until March 2013, 35 thigh ePTFE grafts were placed in 31 chronic hemodialysis patients. Twenty (57%) were women, mean age 58.7 ± 14.5, dialysis vintage 11.9 ± 7.3 years, mean number of previous vascular accesses 4.4 ± 1.9. Two of the 35 (5.7%) grafts were lost to follow-up, immediate failure occurred in 1/35 (2.8%) grafts, and thrombosis appeared within 30 days in 2/35 (5.7%) grafts. Four of the 31 patients died with functioning grafts, while in 9/31 patients the grafts are still patent. In the remaining 17 AV grafts that thrombosed, no surgical intervention was performed in 8/17, while 18 thrombectomies (two per graft) were performed in 9/17 to maintain graft patency. The immediate success rate was 97.1%. Primary patency was from 0-3251 days, on average 906 ± 898, median 472, cumulative patency (N = 33) was from 0-3251 days, on average 1174 ± 954, median 966. Cumulative patency of the grafts that were patent for more than 30 days (N = 30) was from 153-3251 days, on average 1298 ± 921, median 1207. The ePTFE graft survival after the 1st year was 78%, after the 2nd year 74%, after the 3rd year 66%, after the 4th year 56%, after the 5th year 52%, and after the 9th year 13 %. The longest patency was 3251 days without any intervention. Steal syndrome occurred in two patients after 2522 and 275 days after fistula placement.